10-Q: Immix Biopharma Reports Q3 Loss, Raises Capital, Advances CAR-T

Immix Biopharma reported increased Q3 losses and a going concern warning, while securing new capital and advancing its NXC-201 CAR-T therapy with positive clinical data and RMAT designation.

Summary

• Net loss for the three months ended September 30, 2025, increased to $7.59 million from $7.15 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $18.75 million from $16.89 million in the prior year period.
• Cash and cash equivalents decreased to $15.95 million as of September 30, 2025, from $17.68 million as of December 31, 2024.
• The company raised $1.48 million in net proceeds from its At The Market (ATM) offering during Q3 2025, and $2.57 million for the nine months ended September 30, 2025.
• A private placement in September 2025 generated approximately $9.3 million in gross proceeds from the sale of 3,915,604 common shares and warrants to purchase 2,936,709 shares.
• NXC-201, a CAR-T therapy for relapsed/refractory AL Amyloidosis, received Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA in February 2025.
• Clinical data for NXC-201 presented in June 2025 showed a 100% overall response rate (10/10 patients) and a 70% complete response rate (7/10 patients), with no relapses or neurotoxicity observed.
• The company was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) in July 2024, with $4.6 million received as of November 2025 and $3.4 million remaining.
• Management has identified a material weakness in internal control over financial reporting due to limited personnel and inadequate segregation of duties.
• The company expanded its NEXICART-2 clinical trial sites to 18 in July 2025.

Sentiment

Score: 6

Explanation: The filing presents a mixed sentiment. Strong positive clinical data and regulatory designations for NXC-201, coupled with successful capital raises, are significant advancements. However, the increased net losses, declining cash balance, and explicit 'going concern' warning introduce substantial financial risk and temper overall optimism. The material weakness in internal controls is also a notable concern.

Positives

• NXC-201 received Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA in February 2025, potentially streamlining the path to approval.
• Clinical data for NXC-201 in relapsed/refractory AL Amyloidosis showed a 100% overall response rate and a 70% complete response rate in 10 patients, with no relapses or neurotoxicity.
• The company was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support NXC-201 clinical development, with $4.6 million already received.
• Successful capital raises through an ATM facility ($2.57 million net in nine months) and a private placement (~$9.3 million gross) have bolstered liquidity.
• Expansion of NEXICART-2 clinical trial sites to 18 in July 2025 indicates progress in patient enrollment and broader reach for the study.

Negatives

• Net loss increased to $7.59 million for the three months ended September 30, 2025, from $7.15 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $18.75 million from $16.89 million in the prior year period.
• Cash and cash equivalents decreased to $15.95 million as of September 30, 2025, from $17.68 million as of December 31, 2024.
• The company has an accumulated deficit of $93.78 million as of September 30, 2025, indicating sustained losses since inception.
• Interest income decreased significantly to $84,539 for the three months and $338,814 for the nine months ended September 30, 2025, due to lower cash balances.

Risks

• Management believes there is substantial doubt about the company's ability to continue as a going concern through at least the next twelve months from the filing date.
• The company will need to raise substantial additional capital to fund operations beyond Q4 2026, and there is no assurance such funding will be available on reasonable terms.
• Future equity or convertible debt financings will dilute existing stockholders' ownership interests.
• A material weakness in internal control over financial reporting exists due to the company's small size, limited personnel, and inadequate segregation of duties.
• The existence of 2,958,230 vested options and 5,247,870 outstanding warrants could lead to significant dilution and stock price overhang if exercised.
• The company faces significant penalties and damages if the registration statement for the resale of shares and warrants from the September 2025 private placement is not timely declared effective or available for sale.

Future Outlook

Management expects to incur losses for the next twelve months and believes current capital resources are insufficient to sustain operations through at least the next twelve months from the filing date. The company plans to seek additional capital through equity and debt securities, third-party funding, and collaborations. Future funding requirements are dependent on the scope and timing of clinical trials, manufacturing costs, intellectual property protection, and commercialization efforts. The company's existing cash, CIRM grant funding, and ATM proceeds are expected to fund planned operating expenses into the fourth quarter of 2026.

Management Comments

• "Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures in AL Amyloidosis and other serious diseases, as we believe patients are waiting."
• "Management expects the Company to incur losses in the period ending twelve months from this filing and believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing."
• "Accordingly, management believes that there is substantial doubt regarding the Companys ability to continue operating as a going concern through at least the next twelve months from the date of this filing."

Industry Context

Immix Biopharma operates in the highly competitive and dynamic clinical-stage biopharmaceutical industry, specifically focusing on CAR-T cell therapy for AL Amyloidosis and other serious diseases. The market for amyloidosis therapies is estimated at $3.6 billion, projected to reach $6 billion by 2027. NXC-201's RMAT and Orphan Drug Designations position it favorably for accelerated development and market exclusivity, which are critical advantages in the biopharma sector. The company's strategy to develop NXC-201 and other cell therapy candidates in indications where CAR-T is not yet approved aligns with broader industry trends seeking to expand CAR-T applications beyond traditional hematological malignancies. The positive clinical data for NXC-201 suggests potential leadership in the AL Amyloidosis space, where no FDA-approved drugs currently exist for relapsed/refractory patients.

Comparison to Industry Standards

• NXC-201's 100% overall response rate and 70% complete response rate in 10 relapsed/refractory AL Amyloidosis patients are highly encouraging, especially given the lack of FDA-approved therapies for this specific patient population. This data compares favorably to existing treatments for other CAR-T indications, such as multiple myeloma, where CAR-T therapies like Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel) have demonstrated high response rates, but for a different disease context.
• The FDA's RMAT designation for NXC-201 is a significant industry benchmark, indicating the therapy addresses an unmet medical need and has preliminary clinical evidence of potential to address serious conditions. This designation is comparable to those received by other leading regenerative medicine products, facilitating closer FDA collaboration and potential expedited approval pathways.
• The company's cash burn rate and 'going concern' warning are common challenges for early-stage biopharmaceutical companies, particularly those in capital-intensive clinical development phases. This financial position is not unusual for companies heavily invested in R&D without commercialized products, but it highlights the critical need for continuous capital raises, a standard practice in the industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently aware of any material legal proceedings or claims that would have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• Employment Agreement with Ilya Rachman (CEO) and Management Services Agreement with Alwaysraise LLC, an entity of which Gabriel Morris (CFO) is the sole member, detailing their compensation and terms of service.
• Offer letter to Graham Ross Oncology Consulting Services Ltd., of which Graham Ross (Acting Chief Medical Officer) is the sole member, for consultative services.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from future equity raises and exercise of outstanding options/warrants. The 'going concern' warning poses a substantial risk to investment value. Positive clinical data for NXC-201 could drive future value if commercialized.
• **Employees/Management:** Stock option vesting terms clarified for Change in Control events provide enhanced incentives and protection. Increased salaries for CEO and CFO reflect ongoing compensation adjustments.
• **Customers (Future):** Successful development and commercialization of NXC-201 could provide a much-needed therapy for patients with relapsed/refractory AL Amyloidosis, addressing a significant unmet medical need.
• **Creditors/Lenders:** The 'going concern' warning and need for additional financing may increase perceived credit risk.
• **Regulatory Bodies:** RMAT and Orphan Drug Designations indicate positive engagement with regulatory authorities and potential for expedited review processes.

Next Steps

• Continue clinical development of NXC-201 in AL Amyloidosis and other serious diseases.
• Pursue development of additional cell therapy candidates.
• Seek additional capital through various financing sources to fund operations.
• Remediate the identified material weakness in internal control over financial reporting by establishing additional segregation of duties and upgrading IT general controls.
• Work to have the registration statement for the September 2025 private placement shares and warrants declared effective by the SEC to avoid liquidated damages.

Key Dates

Recommendation

The company presents a high-risk, high-reward profile. The clinical data for NXC-201 is exceptionally strong, with 100% overall response and 70% complete response rates in a challenging indication (relapsed/refractory AL Amyloidosis) that lacks approved therapies. RMAT and Orphan Drug Designations further de-risk the regulatory pathway and offer significant market exclusivity potential. However, the explicit 'going concern' warning, coupled with increased net losses and a declining cash balance, highlights severe liquidity challenges. While recent capital raises provide some runway, the need for substantial additional financing and the potential for significant dilution are ongoing concerns. The material weakness in internal controls also adds a layer of operational risk. For a seasoned investor, the promising clinical pipeline warrants continued observation, but the financial instability suggests a 'hold' rather than 'buy' until a clearer path to sustainable funding and operational efficiency is demonstrated. A 'strong buy' would be premature given the going concern risk, and a 'sell' would disregard the significant clinical progress and market potential.

Keywords

CAR-T therapy, AL Amyloidosis, NXC-201, Biopharmaceutical, Clinical-stage, RMAT Designation, Orphan Drug Designation, SEC 10-Q, Biotech, Oncology, Cell therapy, Going concern, Capital raise, Private placement, Stock options, Warrants, Clinical trials